期刊文献+

根治性肾切除术及腔静脉癌栓清除术的麻醉方法及效果

Anesthetic methods and effects of radical nephrectomy and thrombectomy of vena cava tumor
暂未订购
导出
摘要 目的总结根治性肾切除术及腔静脉癌栓清除术的麻醉要点。方法回顾性分析我院14例行根治性肾切除术及腔静脉癌栓清除术患者的临床资料,观察患者的手术情况。结果 14例患者手术均成功,手术时间为4.0~10.6 h,平均(7.6±1.8)h;术中出血量为400~11 000 m L,平均(3 067±2 524)m L;输血量为400~9 200 m L,平均(2 939±2 129)m L;手术中未发生癌栓脱落栓塞;术中并发症主要有低血压、低温、代谢性酸中毒、低血钙、高血钾、凝血功能障碍等。结论术前充分了解癌栓分级,选择适当的麻醉方式和麻醉药物,维持循环稳定,预防和及早发现癌栓脱落,积极对症治疗相关并发症是根治性肾切除术及腔静脉癌栓清除术麻醉的关键。 Objective To summarize the main points of anesthesia in radical nephrectomy and thrombectomy of vena cava tumor. Methods The clinical data of 14 cases of patients with radical nephrectomy and thrombectomy of vena ca va tumor in our hospital was retrospectively analyzed. The patients' surgery situations were observed. Results The surgeries of all patients were successful, no tumor thrombus embolization occurred during surgery. The operation time ranged from 4.0 to 10.6 h, median time was(7.6±1.8) h. The blood loss ranged from 400 to 11 000 m L, median amount was(3 067±2 524) m L.The blood transfusion ranged from 400 to 9 200 m L, median amount was(2 939 ±2 129) m L. The main intraoperative complications were hypotension, hypothermia, metabolic acidosis, hypocalcemia, hyperkalemia, coagulation disorders and so on. Conclusion The key of anesthesia in radical nephrectomy and thrombectomy of vena cava tumor is fully understanding the grade of tumor thrombus, choosing appropriate anesthesia methods and anesthetics, maintaining the stability of cycle,preventing and early detection of cancer embolus off, and actively treating complications.
作者 沈利娟
机构地区 新桥医院麻醉科
出处 《临床医学研究与实践》 2017年第33期67-68,共2页 Clinical Research and Practice
关键词 肾癌 腔静脉癌栓 肾切除术 kidney cancer thrombectomy of vena cava tumor nephrectomy
  • 相关文献

参考文献1

二级参考文献12

  • 1吴剑波,类维富,赵丽云,孙宝柱.热处理对回收血中肿瘤株细胞的杀伤作用和对红细胞Na^+-K^+-ATP酶活性的影响[J].中华麻醉学杂志,2006,26(3):258-260. 被引量:5
  • 2Esper SA, Waters JH. Intra-operative cell salvage : a fresh look at the indications and contraindications [ J ]. Blood Transfus, 2011, 9 : 139-147.
  • 3Ashworth A, Klein AA. Cell salvage as part of a blood conservation strategy in anaesthesia [ J]. Br J Anaesth, 2010, 104: 401-416.
  • 4Waters JH, Yazer M, Chen YF, et al. Blood salvage and cancer surgery: a meta-analysis of available studies [ J ]. Transfusion (Paris), 2012, 52: 2167-2173.
  • 5Hildebrandt B, Wust P, Ahlers O, et al. The cellular and molecular basis of hyperthermia [ J ]. Crit Rev Oncol Hematol, 2002, 43 : 33-56.
  • 6Tsehoep-Lechner KE, Milani V, Berger F, et al. Gemcitabine and cisplatin combined with regional hyperthermia as second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer[ J]. Int J Hyperthermia, 2013, 29 : 8-16.
  • 7Santeufemia DA, Lumachi F, Basso SM, et al. Cytoreductive surgery with hyperthermie intraperitoneal chemotherapy as salvage treatment for a late wound recurrence of endometrial cancer [ J ]. Antieancer Res, 2013, 33: 1041-1044.
  • 8American Association of Blood Banks. Standards for Blood Banks and Transfusion Services[ M]. 16th ed. Bethesda, Md: American Association of Blood Banks, 1994: 32-32.
  • 9Foller M, Braun M, Qadri SM, et al. Temperature sensitivity of suicidal erythrocyte death[ J]. Eur J Clin Invest, 2010, 40: 534- 540.
  • 10Jemal A, Center MM, DeSantis C, et al. Global patterns of cancer incidence and mortality rates and trends [ J ]. Cancer Epidemiol Biomarkers Prey, 2010, 19: 1893-1907.

共引文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部